Publication - Consultation paper
Cardiovascular risk reduction - quality prescribing guidance 2026-2029: consultation
Cardiovascular disease (CVD) is largely preventable, and many modifiable risk factors increase the likelihood of developing CVD. This guide highlights how to support people in modifying risk factors such as diet, healthy weight, alcohol, physical activity, stress and tobacco smoking.
Open
53 days to respond
Respond online
17. Appendix B: Proposed National Therapeutic Indicators
| Risk Factor | Purpose of NTI | Numerator | Denominator |
|---|---|---|---|
| Hypertension | To track the number of individuals prescribed antihypertensive medication for primary prevention Aiming for upwards trend | Number of people prescribed a medication licensed for hypertension not prescribed aspirin, clopidogrel, nicorandil or nitrate | per 1,000 List size (weighted) |
| Obesity | To track number of individuals prescribed incretin based medication for obesity Aiming for upwards trend | Number of people prescribed an incretin based medication not prescribed another diabetic medication (Can include individuals on insulin vials/ short acting to include T1D in cohort) | per 1,000 List size (weighted) |
| Lipids | To track the number of individuals prescribed lipid lowering medication for primary prevention Aiming for upwards trend | Number of people prescribed a medication licensed for lipid lowering not prescribed aspirin, clopidogrel. nicorandil or nitrate | per 1,000 List size (weighted) |
| Diabetes | Already have a suite of NTIs – due update in line with NICE guidance Feb 2026 | - | - |
| Smoking | To track the number of individuals receiving medication for smoking cessation via CP (including GP10) Aiming for upwards trend | Data from PHS, number of individuals receiving treatment per quarter | Board level per 1,000 List size |
Contact
Email: EPandT@gov.scot